IP Library Granted Patent US 8,058,256
Granted Patent B2
US 8,058,256 · App. 12/691,566 · Granted Nov 15, 2011

Polymeric carrier for delivery of small interfering RNA

Assignee: University of Utah Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,058,256
App. No.
12/691,566
Granted
Nov 15, 2011
Kind
B2
Abstract

A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed.

Claims (12)

1. A conjugate comprising a cholesterol residue covalently bonded to oligoarginine through a formate residue linker, wherein the conjugate is represented by the formula:

wherein n is about 4 to 16.

2. The composition of claim 1 wherein n is about 9.

3. The composition of claim 1 wherein the oligoarginine comprises arginine residues in the L form.

4. The composition of claim 1 wherein the oligoarginine comprises arginine residues in the D form.

5. The composition of claim 1 wherein the oligoarginine comprises arginine residues in a mixture of the L and D forms.

6. A method of making a conjugate comprising a cholesterol residue covalently bonded to oligoarginine through a formate residue linker, wherein the conjugate is represented by the formula:

wherein n is about 4 to 16, the method comprising reacting cholesterol chloroformate with oligoarginine, thereby forming an amide bond linking a cholesterol residue and the oligoarginine through the formate residue linker.

7. The method of claim 6 wherein n is about 9.

8. The method of claim 6 wherein the oligoarginine comprises arginine residues in the L form.

9. The method of claim 6 wherein the oligoarginine comprises arginine residues in the D form.

10. The method of claim 6 wherein the oligoarginine comprises arginine residues in a mixture of the L and D forms.

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 5, 2019
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 049961/0523 →
CONFIRMATORY LICENSE Recorded May 12, 2017
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042456/0147 →
CONFIRMATORY LICENSE Recorded May 12, 2017
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042456/0173 →
Continuity (2)
Division 11367228 · Mar 3, 2006
Related Publication 20100130722A1 · May 27, 2010